Ascendis Pharma A/s Stock News

COPENHAGEN, Denmark, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company is scheduled to participate in the Evercore ISI 4th Annual HealthCONx Conference. Company executives will participate in a virtual fireside chat hosted by Evercore ISI.

Related Stocks: ASND , PACB , TVTX , LEGN , KYMR , BLUE , DICE , SRZN , TCRX , TNGX , AMYT , LIFE , APLS , ADCT , PTGX , ASMB , ISEE , SBTX ,

Wall Street brokerages expect Ascendis Pharma A/S (NASDAQ:ASND) to report ($2.78) earnings per share for the current quarter, Zacks reports. Four analysts have issued estimates for Ascendis Pharma A/Ss earnings, with estimates ranging from ($3.71) to ($1.93). Ascendis Pharma A/S reported earnings per share of ($3.15) during the same quarter last year, which would indicate []

Ascendis Pharma (ASND) is seeking approval for TransCon hGH for the treatment of pediatric growth hormone deficiency in Europe.

Ascendis Pharma A/S' (ASND) CEO Jan Mikkelsen on Q3 2021 Results - Earnings Call Transcript

COPENHAGEN, Denmark, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), today announced the U.S. commercial launch of SKYTROFA (lonapegsomatropin-tcgd), its once-weekly treatment fo

– Late-breaking oral presentation will feature a comprehensive review of 58-week results  from the company's Phase 2 PaTH Forward Trial –

COPENHAGEN, Denmark, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new

– Data from subjects with available dual energy x-ray absorptiometry (DXA) scans demonstrated stabilization of BMD, in alignment with observed bone turnover markers previously reported –

The TransCon platform is designed to optimize the delivery of known drugs to target tissues. The valuation of Ascendis Pharma is largely a reflection of the potential of the platform rather than a sum

Ascendis (ASND) plans to develop a sustained-release immunotherapy to treat advanced cancer developed using its TransCon platform.

COPENHAGEN, Denmark, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new

– TransCon IL-2 β/γ  is an investigational long-acting prodrug designed to improve cancer immunotherapy through the sustained systemic release of an IL-2 variant with potential for prolonged acti

COPENHAGEN, Denmark, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new

COPENHAGEN, Denmark, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new t